Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 3 days ago

Akari Therapeutics Plc: MMCAP International Inc. SPC amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 13 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

MMCAP International Inc. SPC amended its Schedule 13G filing on Akari Therapeutics Plc, disclosing a change in its beneficial ownership stake with the SEC under accession number 0000912282-26-001483. The filing, submitted to the U.S. regulator, updates the investment firm's previously reported position in the clinical-stage biopharmaceutical company. The amendment signals a shift in MMCAP's holdings, though the filing itself does not specify the direction or size of the change. Investors will watch for further 13G or 13D filings to gauge whether MMCAP is accumulating or reducing its position in Akari.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

MMCAP International Inc. SPC, Akari Therapeutics Plc